Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.
Identifieur interne : 002721 ( PubMed/Corpus ); précédent : 002720; suivant : 002722Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.
Auteurs : Masayuki Saijo ; Shigeru Morikawa ; Shuetsu Fukushi ; Tetsuya Mizutani ; Hideki Hasegawa ; Noriyo Nagata ; Naoko Iwata ; Ichiro KuraneSource :
- Antiviral research [ 0166-3542 ] ; 2005.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Chlorocebus aethiops, Microbial Sensitivity Tests, Ribavirin (chemistry), Ribavirin (pharmacology), Ribonucleosides (chemistry), Ribonucleosides (pharmacology), SARS Virus (drug effects), SARS Virus (enzymology), SARS Virus (genetics), SARS Virus (physiology), Vero Cells, Virus Replication (drug effects).
- MESH :
- chemical , chemistry : Antiviral Agents, Ribavirin, Ribonucleosides.
- chemical , pharmacology : Antiviral Agents, Ribavirin, Ribonucleosides.
- drug effects : SARS Virus, Virus Replication.
- enzymology : SARS Virus.
- genetics : SARS Virus.
- physiology : SARS Virus.
- Animals, Chlorocebus aethiops, Microbial Sensitivity Tests, Vero Cells.
Abstract
The activity of inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors, mizoribine and ribavirin, against severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) was determined by plaque reduction and yield reduction assays. Mizoribine and ribavirin selectively inhibited replication of SARS-CoV. The 50% inhibitory concentration (IC50) of mizoribine for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, as determined by plaque reduction was 3.5 microg/ml and 16 microg/ml, respectively, and the IC50 of ribavirin for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849 was 20 microg/ml and 80 microg/ml, while the 50% cytotoxic concentration of mizoribine and ribavirin for Vero E6 cells exceeded 200 microg/ml. In a yield reduction assay, mizoribine (10 microg/ml) and ribavirin (40 microg/ml) inhibited the replication of SARS-CoV and reduced the infectious SARS-CoV titers to one-tenth or less. Mizoribine inhibited replication of SARS-CoV more strongly than ribavirin. However, neither drug could completely inhibit replication of SARS-CoV even at concentrations up to 100 microg/ml.
DOI: 10.1016/j.antiviral.2005.01.003
PubMed: 15911031
Links to Exploration step
pubmed:15911031Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.</title><author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name><affiliation><nlm:affiliation>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, Tokyo 208-0011, Japan. msaijo@nih.go.jp</nlm:affiliation></affiliation></author><author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name></author><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name></author><author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name></author><author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name></author><author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name></author><author><name sortKey="Iwata, Naoko" sort="Iwata, Naoko" uniqKey="Iwata N" first="Naoko" last="Iwata">Naoko Iwata</name></author><author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15911031</idno><idno type="pmid">15911031</idno><idno type="doi">10.1016/j.antiviral.2005.01.003</idno><idno type="wicri:Area/PubMed/Corpus">002721</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002721</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.</title><author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name><affiliation><nlm:affiliation>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, Tokyo 208-0011, Japan. msaijo@nih.go.jp</nlm:affiliation></affiliation></author><author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name></author><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name></author><author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name></author><author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name></author><author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name></author><author><name sortKey="Iwata, Naoko" sort="Iwata, Naoko" uniqKey="Iwata N" first="Naoko" last="Iwata">Naoko Iwata</name></author><author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name></author></analytic><series><title level="j">Antiviral research</title><idno type="ISSN">0166-3542</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (pharmacology)</term><term>Chlorocebus aethiops</term><term>Microbial Sensitivity Tests</term><term>Ribavirin (chemistry)</term><term>Ribavirin (pharmacology)</term><term>Ribonucleosides (chemistry)</term><term>Ribonucleosides (pharmacology)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (enzymology)</term><term>SARS Virus (genetics)</term><term>SARS Virus (physiology)</term><term>Vero Cells</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term><term>Ribavirin</term><term>Ribonucleosides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Ribavirin</term><term>Ribonucleosides</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Microbial Sensitivity Tests</term><term>Vero Cells</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The activity of inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors, mizoribine and ribavirin, against severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) was determined by plaque reduction and yield reduction assays. Mizoribine and ribavirin selectively inhibited replication of SARS-CoV. The 50% inhibitory concentration (IC50) of mizoribine for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, as determined by plaque reduction was 3.5 microg/ml and 16 microg/ml, respectively, and the IC50 of ribavirin for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849 was 20 microg/ml and 80 microg/ml, while the 50% cytotoxic concentration of mizoribine and ribavirin for Vero E6 cells exceeded 200 microg/ml. In a yield reduction assay, mizoribine (10 microg/ml) and ribavirin (40 microg/ml) inhibited the replication of SARS-CoV and reduced the infectious SARS-CoV titers to one-tenth or less. Mizoribine inhibited replication of SARS-CoV more strongly than ribavirin. However, neither drug could completely inhibit replication of SARS-CoV even at concentrations up to 100 microg/ml.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15911031</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0166-3542</ISSN><JournalIssue CitedMedium="Print"><Volume>66</Volume><Issue>2-3</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Antiviral research</Title><ISOAbbreviation>Antiviral Res.</ISOAbbreviation></Journal><ArticleTitle>Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.</ArticleTitle><Pagination><MedlinePgn>159-63</MedlinePgn></Pagination><Abstract><AbstractText>The activity of inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors, mizoribine and ribavirin, against severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) was determined by plaque reduction and yield reduction assays. Mizoribine and ribavirin selectively inhibited replication of SARS-CoV. The 50% inhibitory concentration (IC50) of mizoribine for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849, as determined by plaque reduction was 3.5 microg/ml and 16 microg/ml, respectively, and the IC50 of ribavirin for SARS-CoV Frankfurt-1 and SARS-CoV HKU39849 was 20 microg/ml and 80 microg/ml, while the 50% cytotoxic concentration of mizoribine and ribavirin for Vero E6 cells exceeded 200 microg/ml. In a yield reduction assay, mizoribine (10 microg/ml) and ribavirin (40 microg/ml) inhibited the replication of SARS-CoV and reduced the infectious SARS-CoV titers to one-tenth or less. Mizoribine inhibited replication of SARS-CoV more strongly than ribavirin. However, neither drug could completely inhibit replication of SARS-CoV even at concentrations up to 100 microg/ml.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saijo</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, Tokyo 208-0011, Japan. msaijo@nih.go.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morikawa</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fukushi</LastName><ForeName>Shuetsu</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mizutani</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Hideki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Nagata</LastName><ForeName>Noriyo</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Naoko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kurane</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Antiviral Res</MedlineTA><NlmUniqueID>8109699</NlmUniqueID><ISSNLinking>0166-3542</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012263">Ribonucleosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>4JR41A10VP</RegistryNumber><NameOfSubstance UI="C010052">mizoribine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012263" MajorTopicYN="N">Ribonucleosides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>01</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15911031</ArticleId><ArticleId IdType="pii">S0166-3542(05)00027-6</ArticleId><ArticleId IdType="doi">10.1016/j.antiviral.2005.01.003</ArticleId><ArticleId IdType="pmc">PMC7114120</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biochem Pharmacol. 1977 Jun 1;26(11):1071-5</Citation><ArticleIdList><ArticleId IdType="pubmed">880258</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1977 Jun;11(6):946-51</Citation><ArticleIdList><ArticleId IdType="pubmed">879760</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2004 Nov 10;329(1):11-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15476870</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):317-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15030704</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Microbiol. 2003 Aug;52(Pt 8):715-720</Citation><ArticleIdList><ArticleId IdType="pubmed">12867568</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cancer Res. 1977 Mar;37(3):736-43</Citation><ArticleIdList><ArticleId IdType="pubmed">837373</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15215127</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Opin Investig Drugs. 2000 Feb;9(2):221-35</Citation><ArticleIdList><ArticleId IdType="pubmed">11060673</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 1979 Aug 13;89(3):830-6</Citation><ArticleIdList><ArticleId IdType="pubmed">226095</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2003 Dec 15;168(12):1449-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12947028</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 1993 Sep;168(3):641-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8354905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1988 Apr;32(4):492-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2837139</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Chem Chemother. 2002 Nov;13(6):345-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12718406</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Z Naturforsch C J Biosci. 2002 Sep-Oct;57(9-10):902-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12440731</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1982 Jan;21(1):66-73</Citation><ArticleIdList><ArticleId IdType="pubmed">6282209</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Aug 6;320(4):1199-203</Citation><ArticleIdList><ArticleId IdType="pubmed">15249217</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pediatr Int. 2002 Apr;44(2):196-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11896886</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Transplant Proc. 1990 Aug;22(4):1682-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2167528</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2004 Jul;8(4):223-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15234326</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>CMAJ. 2003 Nov 25;169(11):1165-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14638651</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jun 14;361(9374):2045-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12814717</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1164-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15031783</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4197928</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15144898</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1983 Sep;24(3):353-61</Citation><ArticleIdList><ArticleId IdType="pubmed">6615611</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002721 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002721 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15911031
|texte= Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15911031" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |